AGL Stock Overview
A medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 1 more risk
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
My Notes
Capture your thoughts, links and company narrative
ANGLE plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.13 |
| 52 Week High | UK£0.25 |
| 52 Week Low | UK£0.071 |
| Beta | 0.42 |
| 1 Month Change | 0% |
| 3 Month Change | 19.05% |
| 1 Year Change | -27.54% |
| 3 Year Change | -83.55% |
| 5 Year Change | -79.51% |
| Change since IPO | -91.64% |
Recent News & Updates
Recent updates
Here's Why We're Watching ANGLE's (LON:AGL) Cash Burn Situation
Jan 22
Will ANGLE (LON:AGL) Spend Its Cash Wisely?
Sep 27We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Mar 20Will ANGLE (LON:AGL) Spend Its Cash Wisely?
Dec 02We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Aug 11We Think ANGLE (LON:AGL) Needs To Drive Business Growth Carefully
Feb 28ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
Jul 16ANGLE (LON:AGL) Is In A Good Position To Deliver On Growth Plans
Aug 23We're Not Very Worried About ANGLE's (LON:AGL) Cash Burn Rate
May 02What Type Of Shareholders Make Up ANGLE plc's (LON:AGL) Share Registry?
Feb 14
We're Keeping An Eye On ANGLE's (LON:AGL) Cash Burn Rate
Dec 22Shareholder Returns
| AGL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -10.7% | 2.3% | -0.2% |
| 1Y | -27.5% | -6.3% | 10.8% |
Return vs Industry: AGL underperformed the UK Medical Equipment industry which returned -6.3% over the past year.
Return vs Market: AGL underperformed the UK Market which returned 10.8% over the past year.
Price Volatility
| AGL volatility | |
|---|---|
| AGL Average Weekly Movement | 11.4% |
| Medical Equipment Industry Average Movement | 6.7% |
| Market Average Movement | 4.6% |
| 10% most volatile stocks in GB Market | 10.6% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: AGL's share price has been volatile over the past 3 months compared to the UK market.
Volatility Over Time: AGL's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of UK stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1994 | 150 | Andrew David Newland | angleplc.com |
ANGLE plc, a medical diagnostic company, engages in developing cancer diagnostics products in the United Kingdom, Europe, North America, and internationally. The company develops Parsortix PC1 systems, a medical device for the capture and harvest of intact circulating tumour cells (CTCs) from metastatic breast cancer patient blood for subsequent user-validated analysis. It also provides Portrait+ CTC Staining kit, a ready-to-use laboratory kit with high analytical sensitivity and specificity for the identification, characterization, and enumeration of epithelial and mesenchymal transition; and CellKeep Slide, a CTC harvesting technology.
ANGLE plc Fundamentals Summary
| AGL fundamental statistics | |
|---|---|
| Market cap | UK£41.93m |
| Earnings (TTM) | -UK£18.03m |
| Revenue (TTM) | UK£2.02m |
19.9x
P/S Ratio-2.2x
P/E RatioIs AGL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| AGL income statement (TTM) | |
|---|---|
| Revenue | UK£2.02m |
| Cost of Revenue | UK£2.56m |
| Gross Profit | -UK£538.00k |
| Other Expenses | UK£17.49m |
| Earnings | -UK£18.03m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.056 |
| Gross Margin | -26.58% |
| Net Profit Margin | -890.91% |
| Debt/Equity Ratio | 0% |
How did AGL perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/20 20:00 |
| End of Day Share Price | 2025/02/20 00:00 |
| Earnings | 2024/06/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ANGLE plc is covered by 7 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Samuel England | Berenberg |
| Navid Malik | Cavendish Historical (Cenkos Securities) |
| Lucy-Emma Mary Codrington-Bartlett | Edison Investment Research |